BMRN vs TSHA · P/E 40, rev $1.76B vs $640.7M cap
Biomarin Pharmaceutical Inc (BMRN) versus Taysha Gene Therapies Inc (TSHA) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Taysha Gene Therapies Inc (TSHA) is a biotechnology company listed on US.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported TSHA revenue for 2026-06-30 was $0. Net income was -$89.0M. TSHA currently screens at market cap $640.7M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. TSHA currently screens at market cap $640.7M.
Not investment advice. Open the BMRN and TSHA stock pages for the full models.
Not investment advice.